Salamanca

• GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended
  2023-507086-26-00 7 2021-03-09 Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell L
• A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and … Ended
  2023-504403-92-00 1 2021-02-15 Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymp
• A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations Ended
  2024-516369-36-00 3 2021-02-09 - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferativ
• Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure Ended
  2023-504165-23-00 5 2021-02-08 Acute decompensated heart failure
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• Mogamulizumab Every 4 Week dosing in Participants with R/R CTCL Ended
  2024-515921-27-00 4 2021-01-13 Mycosis fungoides/Sezary syndrome recurrent
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaps … Ended
  2024-515582-33-00 1 2020-10-26 Relapsed/Refractory Multiple Myeloma (RRMM)
• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple My … Ended
  2023-504571-25-00 3 2020-10-20 Relapsed or Refractory Multiple Myeloma
• Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma Ended
  2022-502053-34-00 1 2020-07-13 Multiple Myeloma (MM)
• A Phase 3 Study of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in AdultsUndergoin … Ended
  2024-514471-18-00 5 2020-05-13 Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended
  2023-508993-27-00 4 2020-01-17 Chronic myelogenous leukemia
• A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) … Ended
  2024-512537-33-00 5 2019-11-28 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 5 2019-06-12 Multiple myeloma (MM) with at least 2 prior therapies including an imm
• The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft‑versus-host disease (GVHD) in patients receiving hematopoie … Ended
  2024-511164-92-00 10 2019-05-17 Acute Graft versus host disease
• Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable Ended
  2024-513731-24-00 4 2019-05-14 Non-small cell lung cancer (NSCLC)
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 5 2019-01-25 Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
• A study to assess the efficacy and safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma whi … Ended
  2023-505183-10-00 4 2019-01-04 Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM)
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 4 2018-07-09 Relapsed/Refractory Mantle Cell Lymphoma
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment … Ended
  2023-506564-14-00 1 2018-05-16 Relapsed and refractory multiple myeloma (RRMM)
• A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not R … Ended
  2023-508727-12-00 4 2018-04-12 Relapsed and refractory multiple myeloma (RRMM)

Showing 433–456 of 470 trials